Empirical performance of the calibrated self-controlled cohort analysis within temporal pattern discovery: Lessons for developing a risk identification and analysis system

Drug Safety

Volumn 36, Issue SUPPL.1, 2013, Pages

  Norén, G Niklas ^a,b   Bergvall, Tomas ^a   Ryan, Patrick B ^c,f   Juhlin, Kristina ^a   Schuemie, Martijn J ^d,f   Madigan, David ^e,f  

^a UPPSALA MONITORING CENTRE   (Sweden)

^b STOCKHOLM UNIVERSITY   (Sweden)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROMYCIN; ISONIAZID; LISINOPRIL; PRIMIDONE; SALMETEROL; SITAGLIPTIN;

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; CONCEPTUAL FRAMEWORK; CONTROLLED STUDY; DATA BASE; DRUG EXPOSURE; DRUG SURVEILLANCE PROGRAM; ELECTRONIC MEDICAL RECORD; HUMAN; LIVER INJURY; MEASUREMENT ACCURACY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRESCRIPTION; PRIORITY JOURNAL; REGISTRATION; RISK ASSESSMENT; SELF CONTROLLED COHORT ANALYSIS; SENSITIVITY AND SPECIFICITY; TEMPORAL PATTERN DISCOVERY; UPPER GASTROINTESTINAL BLEEDING;

AREA UNDER CURVE; BIAS (EPIDEMIOLOGY); CALIBRATION; COHORT STUDIES; DATABASES, FACTUAL; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ELECTRONIC HEALTH RECORDS; HUMANS; RESEARCH DESIGN; RISK ASSESSMENT;

EID: 84892944187     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0095-x     Document Type: Article

References (27)

1. Edwards IR, Lindquist M, Wiholm BE, Napke E. Quality criteria for early signals of possible adverse drug reactions. Lancet. 1990;336(8708):156-8.
2. Rawlins MD. Spontaneous reporting of adverse drug reactions. I: The data. Brit J Clin Pharmacol. 1988;26(1):1-5.
3. Meyboom RH, Lindquist M, Egberts AC. An ABC of drugrelated problems. Drug Saf. 2000;22(6):415-23.
4. Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013;93(6):539-46.
5. Public Law 110-85: Food and Drug Administration Amendments Act of 2007. 2007.
6. Woodcock J, Behrman RE, Dal Pan GJ. Role of postmarketing surveillance in contemporary medicine. Annu Rev Med. 2011; 62:1-10.
7. Norén GN, Hopstadius J, Bate A, Star K, Edwards IR. Temporal pattern discovery in longitudinal electronic patient records. Data Min Knowl Discov. 2010;20(3):361-87.
8. Norén GN, Bate A, Hopstadius J, Star K, Edwards IR. Temporal pattern discovery for trends and transient effects: Its application to patient records. In: ACM SIGKDD international conference on knowledge discovery and data mining, KDD '08. Las Vegas: ACM; 2008. p. 963-71.
9. Suissa S. The case-time-control design. Epidemiology. 1995; 6(3):248-53.
10. Ryan PB, Madigan D, Stang PE, Marc Overhage J, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: Results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31(30):4401-15.
11. Norén GN, Hopstadius J, Bate A, Edwards IR. Safety surveillance of longitudinal databases: Results on real-world data. Pharmacoepidemiol Drug Saf. 2012;21(6):673-5.
12. Schuemie MJ. Safety surveillance of longitudinal databases: Further methodological considerations. Pharmacoepidemiol Drug Saf. 2012;21(6):670-2.
13. Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Saf. 2013 (in this supplement issue). doi:10.1007/s40264-013-0097-8.
14. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55.
15. Ryan PB, Schuemie MJ, Madigan D. Empirical performance of a self-controlled cohort method: Lessons for developing a risk identification and analysis system. Drug Saf. 2013 (in this supplement issue). doi:10.1007/s40264- 013-0101-3.
16. Hallas J. Evidence of depression provoked by cardiovascular medication: A prescription sequence symmetry analysis. Epidemiology. 1996;7:5.
17. Farrington CP, Nash J, Miller E. Case series analysis of adverse reactions to vaccines: A comparative evaluation. Am J Epidemiol. 1996;143(11):1165-73.
18. Maclure M. The case-crossover design: A method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133(2):144-53.
19. Tannen RL, Weiner MG, Xie D. Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: Comparison of database and randomised controlled trial findings. BMJ. 2009;338:b81.
20. Schuemie MJ. Safety surveillance of longitudinal databases: Further methodological considerations. Pharmacoepidemiol Drug Saf. 2012;21(6):670-2. doi:10.1002/pds.3259.
21. Tisdale J, Miller D. Drug-induced diseases: Prevention, detection, and management. 2nd ed. USA: American Society of Health- System Pharmacists; 2010.
22. Armstrong B. A simple estimator of minimum detectable relative risk, sample size, or power in cohort studies. Am J Epidemiol. 1987;126(2):356-8.
23. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148(3):839-43.
24. Smith BM, Schwartzman K, Bartlett G, Menzies D. Adverse events associated with treatment of latent tuberculosis in the general population. CMAJ. 2011;183(3):E173-9.
25. Carson JL, Strom BL, Duff A, Gupta A, Shaw M, Lundin FE, et al. Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med. 1993;119(7 Pt 1):576-83.
26. Zorych I, Madigan D, Ryan P, Bate A. Disproportionality methods for pharmacovigilance in longitudinal observational databases. Stat Methods Med Res. 2013;22(1):39-56.
27. Norén GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22(1):57-69.